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Summary
Background Manipulation under anaesthesia and arthroscopic capsular release are costly and invasive treatments for 
frozen shoulder, but their effectiveness remains uncertain. We compared these two surgical interventions with early 
structured physiotherapy plus steroid injection.
Methods In this multicentre, pragmatic, three-arm, superiority randomised trial, patients referred to secondary care 
for treatment of primary frozen shoulder were recruited from 35 hospital sites in the UK. Participants were adults 
(≥18 years) with unilateral frozen shoulder, characterised by restriction of passive external rotation (≥50%) in the 
affected shoulder. Participants were randomly assigned (2:2:1) to receive manipulation under anaesthesia, arthroscopic 
capsular release, or early structured physiotherapy. In manipulation under anaesthesia, the surgeon manipulated the 
affected shoulder to stretch and tear the tight capsule while the participant was under general anaesthesia, 
supplemented by a steroid injection. Arthroscopic capsular release, also done under general anaesthesia, involved 
surgically dividing the contracted anterior capsule in the rotator interval, followed by manipulation, with optional 
steroid injection. Both forms of surgery were followed by postprocedural physiotherapy. Early structured physiotherapy 
involved mobilisation techniques and a graduated home exercise programme supplemented by a steroid injection. 
Both early structured physiotherapy and postprocedural physiotherapy involved 12 sessions during up to 12 weeks. 
The primary outcome was the Oxford Shoulder Score (OSS; 0–48) at 12 months after randomisation, analysed by 
initial randomisation group. We sought a target difference of 5 OSS points between physiotherapy and either form of 
surgery, or 4 points between manipulation and capsular release. The trial registration is ISRCTN48804508.
Findings Between April 1, 2015, and Dec 31, 2017, we screened 914 patients, of whom 503 (55%) were randomly 
assigned. At 12 months, OSS data were available for 189 (94%) of 201 participants assigned to manipulation (mean 
estimate 38·3 points, 95% CI 36·9 to 39·7), 191 (94%) of 203 participants assigned to capsular release (40·3 points, 
38·9 to 41·7), and 93 (94%) of 99 participants assigned to physiotherapy (37·2 points, 35·3 to 39·2). The mean group 
differences were 2·01 points (0·10 to 3·91) between the capsular release and manipulation groups, 3·06 points 
(0·71 to 5·41) between capsular release and physiotherapy, and 1·05 points (–1·28 to 3·39) between manipulation 
and physiotherapy. Eight serious adverse events were reported with capsular release and two with manipulation. At a 
willingness-to-pay threshold of £20 000 per quality-adjusted life-year, manipulation under anaesthesia had the highest 
probability of being cost-effective (0·8632, compared with 0·1366 for physiotherapy and 0·0002 for capsular release).
Interpretation All mean differences on the assessment of shoulder pain and function (OSS) at the primary endpoint 
of 12 months were less than the target differences. Therefore, none of the three interventions were clinically superior. 
Arthoscopic capsular release carried higher risks, and manipulation under anaesthesia was the most cost-effective.
Funding The National Institute for Health Research Health Technology Assessment programme.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
Frozen shoulder, also known as adhesive capsulitis, is a 
painful condition that most commonly affects people in 
the sixth decade of life.1,2 The capsule of the shoulder joint 
becomes inflamed, then scarred and contracted, causing 
pain, stiffness, and loss of function.3 People with frozen 
shoulder can struggle with basic daily activities and have 
sleep disturbance due to shoulder pain.4 The cumulative 
incidence of frozen shoulder has been estimated at 
2·4 per 1000 population per year in the Netherlands,1 
affecting 8·2% of men and 10·1% of women of working 
age.2 The exact cause remains unknown, which is why it 
is often labelled as idiopathic or primary frozen shoulder. 
Recognised associations include diabetes, cardiovascular 
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disease, trauma, stroke, neurosurgery, and thyroid 
disease. Association with diabetes is considered to make 
frozen shoulder more resistant to treatment.5
Diagnosis of frozen shoulder is based on clinical 
features of an insidious onset of deep-seated pain in the 
shoulder and upper arm with increasing stiffness, and 
clinical findings of limited active and passive external 
rotation in the absence of crepitus.6 X-rays are not 
routinely required,7 but can be done to exclude shoulder 
arthritis or posterior dislocation, which could present 
with similar clinical signs.
Frozen shoulder can spontaneously resolve, but 
recovery might be slow or incomplete. Around 40% of 
patients report persistent symptoms even 4 years after 
onset.8 Primarily, the severity of pain and disability 
arising from the restriction of movement drives patients 
to seek treatment.4 A range of treatment options with 
increasing degrees of invasiveness are available, but 
there is uncertainty about when these should be offered 
and their clinical effectiveness or cost-effectiveness.9 
A survey of specialist health professionals that we 
conducted in the UK identified three interventions as 
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Research in context
Evidence before this study
Frozen shoulder is a common and painful condition in which 
movements in the shoulder become restricted. Although it is 
often a self-limiting condition, there can be slow and 
incomplete resolution, during which people can struggle with 
basic daily activities and work, and have disturbed sleep from 
the pain. Generally, conservative treatments are provided in a 
primary care setting in the UK. More invasive, surgical 
treatments, such as manipulation under anaesthesia or 
arthroscopic capsular release, are used in hospital. In 2012, 
we published a systematic review, which concluded that there 
was inadequate evidence for the clinical effectiveness and cost-
effectiveness of different treatment options in the management 
of a primary frozen shoulder, including intensive or invasive 
interventions. We updated that review by searching MEDLINE 
(from 1946 to Dec 6, 2018), Central (from inception to 
Dec 5, 2018), Embase (from 1974 to Dec 7, 2018), PEDro (from 
2009 to Dec 7, 2018), WHO International Clinical Trials Registry 
Platform (from inception to Dec 11, 2018), and Science Citation 
Index and ClinicalTrials.gov (from inception to Dec 7, 2018), 
using the search terms “adhesive capsulitis”, “frozen shoulder”, 
“stiff shoulder”, “bursitis”, and “periarthritis”, with no language 
restriction, to assess the effectiveness of interventions. 
We included hydrodilatation because of its increasing popularity 
despite a paucity of evidence. Nine trials (including UK FROST) 
were included, with the number of participants in other trials 
ranging from 26 to 136. The quality of the trials was variable, 
and considerable heterogeneity of the interventions made it 
difficult to combine studies or draw conclusions. Only two trials 
were pooled in a meta-analysis that compared long-term 
functioning between arthroscopic capsular release and 
physiotherapy plus steroid injection. The pooled effect favoured 
capsular release (standardised mean difference 0·32 SDs, 
95% CI 0·08–0·56), but was smaller in magnitude than the 
clinical threshold of the standard effect size used in UK FROST. 
The evidence of the effectiveness of hydrodilatation from 
four trials was inconclusive.
Following a 2010 national survey of 303 health-care 
professionals in the UK, we determined that physiotherapy, 
manipulation under anaesthesia, and arthroscopic capsular 
release were the more frequently used interventions in a 
secondary care setting. Only 6% of respondents at the time 
suggested hydrodilatation as a comparator. We therefore aimed 
to evaluate the clinical (pain and function) effectiveness and 
cost-effectiveness of physiotherapy compared with the two forms 
of surgery for treating frozen shoulder.
Added value of this study
To our knowledge, UK FROST is the largest randomised trial to 
compare early structured physiotherapy, manipulation under 
anaesthesia, and arthroscopic capsular release. Early structured 
physiotherapy was a multicomponent secondary care 
physiotherapy intervention, including steroid injection, that we 
developed using recommendations from national guidelines 
and a Delphi study of shoulder specialist physiotherapists. 
The two surgical interventions did not have better clinically 
important outcomes for shoulder pain and function compared 
with physiotherapy at 12 months. Arthroscopic capsular release 
carried higher risks. Physiotherapy was a low-cost option that 
could be accessed more quickly but was not clinically superior. 
The health economic comparison found manipulation to be the 
most cost-effective intervention within the UK health-care 
setting. Our embedded qualitative study identified that early 
medical help and quicker access to National Health Service 
(NHS) care pathways was important to patients.
Implications of all the available evidence
UK FROST provides robust evidence that none of the three trial 
treatments were superior on patient-reported outcomes for 
shoulder pain and function at 12 months. However, a marginal 
clinically important benefit of capsular release over physiotherapy 
might exist in the wider population. Our specifically designed 
early structured physiotherapy pathway was accessed more 
quickly than were the surgical options, and was lower in cost; 
therefore, its implementation in clinical practice should be 
carefully considered. Importantly, manipulation under 
anaesthesia was the most cost-effective option. Manipulation 
under anaesthesia is an existing pathway in the NHS and 
requires less theatre time than arthroscopic capsular release. 
Capsular release carries higher risks and costs compared with 
manipulation and physiotherapy, but fewer participants in this 
group required further treatment. Our evidence suggests that 
arthroscopic capsular release should be used more selectively 
when less costly and less invasive interventions fail.
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most commonly used: physiotherapy, manipulation 
under anaesthesia, and arthroscopic capsular release.10 
The UK national physiotherapy guidelines for frozen 
shoulder, based on a systematic review, recommend 
exercise and manual therapy either in isolation or to 
supplement intra-articular injection of glucocorticoid 
(steroid), manipu lation, or capsular release.11 We further 
developed and standardised the non-surgical care 
pathway for this trial to include intra-articular steroid 
injection followed by structured physiotherapy, using the 
best available evidence and consensus from expert 
shoulder physio therapists. We called this early structured 
physiotherapy because it is more quickly accessible 
within secondary care than are the surgical interventions.12 
It is not known whether early structured physiotherapy 
or either of the surgical interventions followed by 
physiotherapy is more effective.13 Systematic reviews 
have identified large gaps in evidence and a need for 
high quality primary research.13,14 With the intention of 
facilitating quicker recovery, manipulation and capsular 
release are increas ingly used despite the dearth of good 
evidence.13,15
We designed the UK Frozen Shoulder Trial (UK 
FROST) to assess the effectiveness and cost-effectiveness 
of three care pathways to treat adults with a frozen 
shoulder: two commonly used surgical interventions 
within the UK National Health Service (NHS) hospitals 
(manipulation and capsular release), and our specifically 
designed non-surgical physiotherapy pathway.
Methods
Study design
This multicentre, pragmatic, superiority randomised 
trial compared three parallel groups for patients referred 
to secondary care for treatment of primary frozen 
shoulder, who were recruited from 35 hospital sites 
in the UK. The trial interventions were delivered by 
90 surgeons and 285 physiotherapists who were experi-
enced in using these treatments. Two additional hospitals 
screened patients but did not recruit to the trial.
Ethics approval was obtained from the National 
Research Ethics Service (NRES Committee North East, 
14/NE/1176), and local site-specific NHS research and 
development approvals were obtained from each partici-
pating site. The study was adopted to the UK Clinical 
Research Network portfolio (17719). Our detailed study 
protocol has been published elsewhere.16
Participants
Patients referred to participating NHS hospitals were 
eligible if they were 18 years or older and presented with 
a clinical diagnosis of unilateral frozen shoulder, charac-
terised by the restriction of passive external rotation in 
the affected shoulder to less than 50% of the opposite 
shoulder,17 for which there was evidence of good inter-
rater agreement.18 Plain radiographs (anteroposterior 
and axillary view) of the affected shoulder were obtained 
to exclude other pathology. Detailed exclusion criteria 
are in the protocol and included bilateral concurrent 
frozen shoulder, having frozen shoulder secondary to 
trauma that required hospital care or secondary to other 
causes, except diabetes (eg, recent breast surgery), not 
having sufficient mental capacity to understand the 
instructions or treatment, not being a resident in a 
catchment area of a trial site, and if any of the trial 
treatments were contraindicated (eg, if patients were 
unfit for anaesthesia or corticosteroid injection). Patients 
with diabetes were included, because this is significantly 
associated with impaired shoulder mobility in this 
patient population.19 Informed written consent was 
obtained from all trial participants by suitably qualified 
local study personnel at each participating site.
Randomisation and masking
After surgeons or physiotherapists confirmed eligibility 
and baseline data was collected for eligible and con-
senting patients, the research nurse accessed a secure 
remote randomisation service via telephone or internet, 
provided by a registered clinical trials unit at the 
University of York. Individual participants were randomly 
assigned with unequal allocation (2:2:1) to arthroscopic 
capsular release, manipulation under anaesthesia, or 
early structured physiotherapy, to allow for different 
effect sizes between groups. Allocation was based on a 
computer-generated randomisation algorithm that used 
random block sizes of 10 and 15 and stratified patients 
by presence of diabetes. Concealment was ensured by 
registering participants before the remote computer-
generated randomisation with randomly varying block 
sizes.
Blinding of participants and clinicians to treatment 
allocation was not possible or desirable in this pragmatic 
trial. Therefore, participants and clinicians were informed 
about treatment allocation immediately after random-
isation.
Procedures
Participants underwent standardised physiotherapy 
programmes in all three groups. The early structured 
physiotherapy and postprocedural physiotherapy pro-
grammes were standardised using evidence from a 
systematic review,13 UK guidelines, and previous surveys 
of UK physiotherapists and Delphi consensus method-
ology.20 The full standard course of early structured 
physiotherapy and postprocedural physiotherapy was 
12 sessions during up to 12 weeks. If the physiotherapist 
and participant were satisfied with their progress, not all 
12 sessions were necessary; otherwise, participants were 
encouraged to attend the full standard course.
In the early structured physiotherapy intervention, at 
the earliest opportunity before starting physiotherapy, 
an intra-articular steroid (glucocorticoid) injection 
was administered with or without imaging guidance, 
depending on usual practice of the hospital site, because 
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914 patients assessed for eligibility
201 randomly assigned to manipulation under 
anaesthesia with steroid injection
203 randomly assigned to arthroscopic capsular 
release with manipulation under anaesthesia
99 randomly assigned to early structured 
physiotherapy with steroid injection
164 received allocated treatment from 58 surgeons 
(median of two patients per surgeon [IQR 1–3]) 
and 148 physiotherapists (median of one patient 
per physiotherapist [IQR 1–2]), with a median of 
seven physiotherapy sessions per patient (IQR 
4–11), across 33 sites (median of four patients per 
site [IQR 3–9])
4 crossed over to early structured physiotherapy
8 recorded as having alternative treatment
5 had other physiotherapy
1 had capsular release without manipulation 
1 had subacromial decompression
1 had steroid injection
162 received allocated treatment from 64 surgeons 
(median of two patients per surgeon [IQR 1–3]) 
and 175 physiotherapists (median of one patient 
per physiotherapist [IQR 1–2]), with a median of 
eight physiotherapy sessions per patient           
(IQR 5–11), across 33 sites (median of five 
patients per site [IQR 2–8])
3 crossed over to manipulation
2 crossed over to early structured physiotherapy 
7 recorded as having alternative treatment
4 had other physiotherapy
2 had steroid injection
1 had capsular release without manipulation
80 received allocated treatment from 78 
physiotherapists (median of one patient per 
physiotherapist [IQR 1–2]), with a median of nine 
physiotherapy sessions per patient (IQR 6–12), 
across 30 sites (median of two patients per site 
[IQR 2–4])
7 crossed over to capsular release with manipulation 
under anaesthesia 
2 recorded as having alternative treatment
1 had hydrodilatation and other physiotherapy
1 had steroid injection
178 completed 3-month follow-up  179 completed 3-month follow-up 90 completed 3-month follow-up
37 did not receive allocated treatment
9 symptoms improved
5 not fit for surgery
4 started alternative treatment
2 change of diagnosis
1 did not want any trial treatment
16 reason unknown
503 randomly assigned
411 excluded 
95 did not meet eligibility criteria*
20 bilateral concurrent frozen shoulder
23 secondary to trauma or other causes
16 trial treatments contraindicated
16 unfit for general anaesthesia
20 not resident in catchment area of a participant trial site 
5 insufficient mental capacity to comply with treatment or data collection
21 had other reason for exclusion
295 declined to participate 
177 completed 6-month follow-up 170 completed 6-month follow-up 83 completed 6-month follow-up
183 completed 12-month follow-up 175 completed 12-month follow-up 88 completed 12-month follow-up
41 did not receive allocated treatment 
7 symptoms improved
5 not fit for surgery
4 another problem intervened
2 change of diagnosis
2 administrative error
1 did not want any trial treatment
1 unable to follow protocol
19 reason unknown
19 did not receive allocated treatment
7 did not start physiotherapy
1 wanted surgery
6 reason unknown
12 did not complete physiotherapy 
7 were not satisfied with progress
1 another problem intervened
4 stopped attending without giving a reason
23 excluded at follow-up
3 withdrew
19 did not return 
1 returned but missing OSS
24 excluded at follow-up
4 withdrew
20 did not return 
9 excluded at follow-up
1 withdrew
8 did not return 
24 excluded at follow-up
7 withdrew 
14 did not return 
3 returned but missing OSS
33 excluded at follow-up
6 withdrew 
23 did not return 
4 returned but missing OSS
16 excluded at follow-up
2 withdrew
14 did not return
18 excluded at follow-up
7 withdrew 
11 did not return
28 excluded at follow-up 
10 withdrew
15 did not return 
3 returned but missing OSS
11 excluded at follow-up 
2 withdrew
8 did not return 
1 returned but missing OSS
12 excluded from analysis because no OSS data at 
any follow-up
12 excluded from analysis because no OSS data at 
any follow-up
6 excluded from analysis because no OSS data at 
any follow-up
189 analysed 191 analysed 93 analysed
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current evidence did not support the superiority of either 
approach.21 Full details about the physiotherapy pro-
grammes are given elsewhere, 12,16 and included infor-
mation on pain management, mobilisation techniques 
(increasingly stretching into the stiff part of the range of 
movement), and a graduated home exercise programme 
that progressed from gentle pendular exercises to firm 
stretching exercises according to the stage of frozen 
shoulder, as is accepted good practice.11,20
Manipulation under anaesthesia and arthroscopic 
capsular release were done as day case surgical procedures 
within 18 weeks of randomisation. In manipulation 
under anaesthesia, the surgeon manipulated the affected 
shoulder in a controlled way to stretch and tear the 
tight capsule while the participant was under general 
anaesthesia, supplemented by an intra-articular steroid 
injection during surgery. If the manipulation was judged 
to be incomplete, the surgeon did not cross over intra-
operatively to capsular release, to allow assessment of 
outcome of the manipulation.
Arthroscopic capsular release was done under general 
anaesthesia by a surgeon to surgically divide the con-
tracted anterior capsule in the rotator interval, followed 
by manipulation under anaesthesia to complete and 
confirm optimal capsular release. Additional procedures, 
such as posterior capsular release and subacromial 
decom pression, were permitted at the discretion of the 
operating surgeon, and were recorded. Supplemen tary 
steroid injections were used at the surgeon’s discretion. 
Both manipulation and capsular release were followed 
by postprocedural physiotherapy, normally beginning 
within 24 h, in which all participants were provided with 
information on pain management and instructions on 
a graduated home exercise programme, as described 
earlier, with the optional addition of mobilisation 
techniques.
All interventions were delivered by participating surgeons 
who were familiar with the surgical procedures (as judged 
by the Principal Investigator at each site) and by qualified 
physiotherapists (ie, not students or assistants). There was 
no minimum number of surgical procedures that the 
surgeon had to have done, and no grades of surgeon were 
excluded. No additional training was required for either 
programme of physio therapy.
Outcomes
The primary outcome was the Oxford Shoulder Score 
(OSS), a 12-item patient-reported outcome measure of 
shoulder pain and function with five response categories 
and an overall scale ranging from 0 (worst) to 48 (best).22 
The primary endpoint was 12 months after random-
isation.
Secondary patient-reported outcome measures were 
the Quick Disabilities of the Arm, Shoulder, and Hand 
(QuickDASH)23 score, as a further region-specific mea s-
ure of response to treatment;24 health-related quality of 
life using the 5-level version of the EuroQOL 5-Dimension 
questionnaire;25 the Numeric Rating Scale for pain;26 and 
the perceived extent of recovery measured by a single 
visual analogue scale (VAS) ranging from 0 (no need to 
seek further treatment) to 100 (definite need). The VAS 
for treatment recovery was purposefully designed for the 
study with input from patients and clinicians. All outcome 
measures were collected at baseline, 3 months, 6 months, 
and 12 months after randomisation. In addition, OSS 
was collected at the start of treatment and 6 months 
after that point. Any compli cations and adverse events 
were recorded. Following completion of the allocated 
intervention, any further treatments for the frozen 
shoulder were recorded.
Statistical analysis
A full description of the sample size calculation and 
statistical analysis plan is in the published protocol.16 The 
sample size was based on the primary outcome measure at 
12 months after randomisation and was calculated using 
a minimum clinically important difference of 5 points in 
OSS when comparing early structured physiotherapy with 
either surgical treatment, or a difference of 4 points when 
comparing the two surgical treatments. The larger differ-
ence when comparing early structured physiotherapy with 
a surgical treatment was required to justify the greater 
costs and potential risks associated with surgery.22 To 
observe the above differences with 90% power and 
two-sided 5% significance, adjusting for a conservative 
estimate (r=0·4) of the correlation between OSS during 
12 months and allowing for 20% loss to follow-up, a total 
sample size of 500 patients was required. No adjustment 
was made for multiple comparisons, owing to the a priori 
specified sequence of treatment comparisons (manipu-
lation vs physiotherapy, capsular release vs physiotherapy, 
and manipulation vs capsular release; results were inter-
preted as if from three independent trials, with inference 
for one comparison independent of the outcome of 
another).27
The analysis of primary and secondary outcomes 
followed intention-to-treat principles, such that compari-
sons were according to the randomised group, irrespective 
of compliance, without imputation for minimal missing 
data, excluding participants for whom no OSS data were 
available. We used a linear mixed model incorporating all 
timepoints and using an unstructured covariance pattern. 
The model adjusted for age (in years), gender (male or 
female), diabetes status (diabetic or non-diabetic), and 
OSS at baseline as fixed effects, and recruitment site 
(35 sites) as a random effect. A single model was used for 
the analysis, and treatment group differences at each 
timepoint were presented as three separate two-way 
comparisons. The OSS at 12 months, QuickDASH, pain 
Figure 1: Trial profile
OSS=Oxford Shoulder Score. *Some patients did not meet multiple eligibility 
criteria. 
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As randomised (n=503) As analysed (n=473)
Manipulation 
under anaesthesia 
(n=201)
Arthroscopic 
capsular release 
(n=203)
Early structured 
physiotherapy 
(n=99)
Manipulation 
under anaesthesia 
(n=189)
Arthroscopic 
capsular release 
(n=191)
Early structured 
physiotherapy 
(n=93)
Gender
Male 72 (36%) 77 (38%) 35 (35%) 68 (36%) 74 (39%) 31 (33%)
Female 129 (64%) 126 (62%) 64 (65%) 121 (64%) 117 (61%) 62 (67%)
Age (years)
Mean (SD) 54·5 (7·7) 53·9 (7·7) 54·5 (7·8) 54·4 (7·3) 54·4 (7·6) 54·8 (7·8)
Median (IQR) 54 (54–60) 54 (54–59) 53 (53–60) 54 (54–60) 55 (55–59) 53 (53–60)
Diabetes
No 141 (70%) 143 (70%) 69 (70%) 131 (69%) 135 (71%) 66 (71%)
Type 1 12 (6%) 12 (6%) 5 (5%) 12 (6%) 11 (6%) 5 (5%)
Type 2 48 (24%) 48 (24%) 25 (25%) 46 (24%) 45 (24%) 22 (24%)
Affected shoulder
Left 127 (63%) 121 (60%) 56 (57%) 119 (63%) 114 (60%) 54 (58%)
Right 73 (36%) 80 (39%) 43 (43%) 69 (37%) 75 (39%) 39 (42%)
Data missing 1 (<0·5%) 2 (1%) 0 1 (1%) 2 (1%) 0
Dominant arm affected
Yes 81 (40%) 82 (40%) 39 (39%) 77 (41%) 76 (40%) 36 (39%)
No 115 (57%) 120 (59%) 59 (60%) 107 (57%) 114 (60%) 56 (60%)
Ambidextrous 0 1 (<1%) 0 0 (0%) 1 (1%) 0
Data missing 5 (2%) 0 1 (1%) 5 (3%) 0 1 (1%)
Duration of symptoms (months)
Patients with data n=196 n=201 n=98 n=185 n=190 n=92
Mean (SD) 10·5 (8·6) 11·3 (10·0) 10·8 (8·8) 10·7 (8·7) 11·3 (10·1) 11·0 (9·0)
Median (IQR) 8 (6–12) 9 (6–12) 8 (6–12) 8 (6–12) 9 (6–12) 8 (6–12)
Range 2–60 0–96 2–72 2–60 2–96 2–72
Duration of symptoms
<9 months 103 (51%) 95 (47%) 51 (52%) 96 (51%) 90 (47%) 48 (52%)
≥9 months 93 (46%) 106 (52%) 47 (47%) 89 (47%) 100 (52%) 44 (47%)
Data missing 5 (2%) 2 (1%) 1 (1%) 4 (2%) 1 (1%) 1 (1%)
X-rays
Anteroposterior view 200 (100%) 201 (99%) 99 (100%) 188 (99%) 190 (99%) 93 (100%)
Axillary view 174 (87%) 179 (88%) 86 (87%) 163 (86%) 169 (88%) 80 (86%)
Modified axillary 29 (14%) 24 (12%) 14 (14%) 27 (14%) 24 (13%) 14 (15%)
Employment status summary
In paid work 129 (64%) 118 (58%) 53 (54%) 124 (66%) 111 (58%) 50 (54%)
Not in paid work 69 (34%) 82 (40%) 46 (46%) 62 (33%) 78 (41%) 43 (46%)
Data missing 3 (1%) 3 (1%) 0 3 (2%) 2 (1%) 0 (0%)
Type of employment
Unskilled manual 17 (8%) 15 (7%) 8 (8%) 16 (8%) 13 (7%) 7 (8%)
Skilled manual 21 (10%) 18 (9%) 18 (18%) 19 (10%) 16 (8%) 17 (18%)
Unskilled non-manual 19 (9%) 17 (8%) 4 (4%) 19 (10%) 17 (9%) 4 (4%)
Skilled non-manual 41 (20%) 37 (18%) 13 (13%) 40 (21%) 37 (19%) 12 (13%)
Professional 13 (6%) 19 (9%) 10 (10%) 13 (7%) 18 (9%) 10 (11%)
Other 20 (10%) 17 (8%) 10 (10%) 18 (10%) 15 (8%) 10 (11%)
Currently taking steroids for affected shoulder
Yes 2 (1%) 7 (3%) 0 2 (1%) 7 (4%) 0
No 196 (98%) 195 (96%) 99 (100%) 184 (97%) 183 (96%) 93 (100%)
Data missing 3 (1%) 1 (<0·5%) 0 3 (2%) 1 (1%) 0
(Table 1 continues on next page)
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Numeric Rating Scale, and extent of recovery VAS were 
analysed in a similar way.
To address the effect of delays in receiving the allocated 
treatment, we used a separate, secondary, intention-to-
treat, linear mixed model, which incorporated time as a 
continuous variable. This model included data from all 
available timepoints for each participant (additionally 
including the OSS score before treatment and 6 months 
after treatment) and adjusted for the same covariates as 
the primary analysis model. Treatment effect estimates 
were extracted at 3 months, 6 months, and 12 months 
after randomisation.
Complier Average Causal Effect (CACE) analysis 
investi gated the effect of adherence with early struc-
tured physiotherapy on the OSS at 12 months using 
instrumental variable regression. Further sensitivity 
analyses included additional adjustment for predictors of 
missing data, exclusion of response data received beyond 
6 weeks of each intended follow-up, and adjustment 
for observed baseline differences in employment status. 
Subgroup analyses explored whether the treatment 
response was influenced by presence of diabetes, 
previous physiotherapy treatment, and participant treat-
ment preference at baseline by including treatment by 
subgroup interactions in the model. Adverse events 
and complications were listed by allocated group and 
compared by the χ² test.
All statistical testing was done at the two-sided 
5% significance level and estimates given with 95% CIs 
using Stata 15. The statistical analysis plan was approved 
by an independent data monitoring committee and the 
trial steering committee. The trial is registered with the 
International Standard Randomised Controlled Trial 
Register (ISRCTN48804508).
As randomised (n=503) As analysed (n=473)
Manipulation 
under anaesthesia 
(n=201)
Arthroscopic 
capsular release 
(n=203)
Early structured 
physiotherapy 
(n=99)
Manipulation 
under anaesthesia 
(n=189)
Arthroscopic 
capsular release 
(n=191)
Early structured 
physiotherapy 
(n=93)
(Continued from previous page)
Had steroid injection for affected shoulder
Yes 97 (48%) 117 (58%) 55 (56%) 93 (49%) 112 (59%) 53 (57%)
No 102 (51%) 86 (42%) 44 (44%) 94 (50%) 79 (41%) 40 (43%)
Data missing 2 (1%) 0 0 2 (1%) 0 0
Previous physiotherapy for affected shoulder
Yes 125 (62%) 124 (61%) 59 (60%) 117 (62%) 117 (61%) 58 (62%)
No 76 (38%) 77 (38%) 39 (39%) 72 (38%) 73 (38%) 35 (38%)
Data missing 0 2 (1%) 1 (1%) 0 1 (1%) 0
Number of weeks had shoulder 
problem (median [IQR])
32 (24–52) 35 (24–52) 32 (24–48) 34 (24–52) 36 (24–52) 32 (24–48)
Similar shoulder problem on the opposite side
Yes 62 (31%) 53 (26%) 13 (13%) 59 (31%) 51 (27%) 12 (13%)
No 132 (66%) 146 (72%) 85 (86%) 124 (66%) 136 (71%) 80 (86%)
Data missing 7 (3%) 4 (2%) 1 (1%) 6 (3%) 4 (2%) 1 (1%)
Oxford Shoulder Score (0–48)*
Mean (SD) 20·4 (8·9) 19·2 (7·7) 20·3 (8·0) 20·6 (8·9) 19·2 (7·5) 20·3 (8·1)
Median (IQR) 20 (14–27) 19 (13–25) 20 (15–26) 20 (14–27) 19 (14–25) 20 (15–26)
QuickDASH score (0–100)
Patients with data n=192 n=197 n=96 n=181 n=187 n=90
Mean (SD) 57·0 (21·0) 61·7 (18·5) 59·4 (19·7) 56·8 (21·1) 61·3 (18·5) 59·1 (20·0)
Median (IQR) 59 (42–75) 64 (52–75) 60 (46–73) 59 (43–73) 64 (50–73) 59·5 (46–73)
Pain Numeric Rating Scale (0–10)
Patients with data n=199 n=201 n=99 n=187 n=190 n=93
Mean (SD) 6·8 (2·2) 7·0 (1·9) 6·9 (2·4) 6·7 (2·3) 7·0 (1·9) 6·8 (2·4)
Median (IQR) 7 (5–8) 7 (6–8) 7 (5–8) 7 (5–8) 7 (6–8) 7 (5–8)
Symptom severity (0–100)
Patients with data 198 201 99 186 189 93
Mean (SD) 83·8 (21·8) 86·2 (20·1) 89·2 (15·4) 83·9 (22·1) 86·0 (20·4) 89·0 (15·5)
Median (IQR) 90 (75–100) 95 (80–100) 100 (80–100) 90 (80–100) 95 (80–100) 100 (80–100)
Data are n (%) or median (IQR) unless otherwise specified. QuickDASH=Quick Disabilities of the Arm, Shoulder, and Hand. *Includes two imputed missing baseline scores 
(one for manipulation and one for capsular release). 
Table 1: Baseline characteristics
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Health economic analyses were conducted in 
accordance with the National Institute for Health and 
Care Excellence (NICE) reference case standards.28 The 
base-case analysis was conducted on an intention-to-treat 
basis with multiple imputation for missing data, which 
was assumed missing at random. The analysis was 
conducted from an NHS and Personal Social Services 
perspective and included the cost of the initial inter-
vention, hospital stays and outpatient appointments after 
initial intervention, and visits to pri mary and community 
health-care professionals during one year. Costs were 
calculated using national UK unit costs expressed in 
British Pound Sterling (GBP) at the 2018 price. Outcomes 
were measured in terms of quality-adjusted life-years 
(QALYs) during one year. We used a mapping function to 
derive utilities29,30 and the area under the curve method to 
estimate QALYs.
We used differences in mean costs and mean QALYs at 
12 months to derive the incremental cost-effectiveness 
ratios, which represent the greater benefit per GBP 
spent. This ratio was estimated by comparing mean 
differences in expected costs and QALYs between 
treatment groups. The mean estimates and their 95% CIs 
were generated using seemingly unre lated regression. 
Decisions about whether a treatment is efficient (ie, value 
for money) are determined according to whether the cost 
per QALY gained (ie, the incremental cost-effectiveness 
ratio) is below some threshold value. The threshold 
represents the opportunity cost of delivering an inter-
vention (ie, the health forgone from providing this 
intervention). At present, the NICE threshold ranges 
between £20 000 and £30 000 per QALY. According to the 
current established decision rules, if the estimated cost 
per QALY is below the £20 000 threshold, the intervention 
would be considered cost-effective in terms of QALYs 
gained.
To compute the probability of each intervention being 
cost-effective, we did the seemingly unrelated regression 
within a bootstrapping approach on five imputed data 
sets to generate 100 000 replicates of incremental costs 
and benefits. The probability that each intervention 
is cost-effective was reported at the cost-effectiveness 
threshold applied by NICE (£20 000 to £30 000 per QALY) 
and at a further recommended threshold of £13 000 per 
QALY.31,32
Role of the funding source
The funders monitored the trial progress but had no role 
in the study design, data collection, data analysis, data 
interpretation, writing and approving the report, or the 
decision to submit for publication. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit for publi-
cation.
Results
Between April 1, 2015, and Dec 31, 2017, we screened 
914 patients with a frozen shoulder, from whom we 
randomly assigned 503 (55%) patients, including 201 to 
manipulation, 203 to capsular release, and 99 to early 
structured physiotherapy (figure 1). Follow-up was com-
pleted on Jan 31, 2019. The baseline characteristics, 
distribution of patients across sites, and number of 
treating surgeons and physiotherapists per patient are 
shown in table 1.
Within the allocated treatment groups, 164 (82%) of 
201 participants completed manipulation, 162 (80%) of 
203 participants completed capsular release, and 80 (81%) 
of 99 participants completed physiotherapy (figure 1). In 
addition, 164 (82%) participants had a steroid injection 
in the manipulation group, 45 (22%) in the capsular 
release group, and 79 (80%) in the physiotherapy group. 
Further details about the delivery, type, and dose of 
the steroid are provided in the appendix (p 2). 16 (3%) of 
503 partici pants crossed over to a different trial treat-
ment, and 17 (3%) received an alternative treatment. 
Overall, 64 (13%) participants did not receive any 
treatment. Waiting times to the start of each randomised 
Manipulation 
under anaesthesia 
(n=164)
Arthroscopic 
capsular release 
(n=162)
Early structured 
physiotherapy 
(n=80) 
Arthroscopic capsular release 7 (4%) 0 5 (6%)
Manipulation under anaesthesia 1 (1%) 1 (1%) 3 (4%)
Further non-surgical treatment
Steroid injection 3 (2%) 3 (2%) 3 (4%)
Glenohumeral joint injection 2 (1%) 0 0
Ultrasound guided injection 0 1 (1%) 1 (1%)
Other or further physiotherapy 2 (1%) 3 (2%) 6 (8%)
Rheumatology clinic 0 0 1 (1%)
Total number of further treatments 15 8 19
Total number of patients having one or 
more further treatments (% of randomised)
14/201 (7%) 8/203 (4%) 15/99 (15%)
Data are n (%). 
Table 2: Further treatments for patients who completed treatment and as per randomised groups
Figure 2: Primary outcome: Oxford Shoulder Score
Data points show means and error bars represent 95% CIs.
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treatment varied considerably. Participants waited a 
median of 14 days (IQR 7–22) for physiotherapy, 57 days 
(IQR 35–89) for manipulation, and 72 days (IQR 42–116) 
for capsular release (appendix p 1). Following completion 
of their ran dom ised treatment, some participants 
received further treatment (table 2). The most further 
treatments were received by participants in the physio-
therapy group (n=15 [15%]), followed by the manipulation 
group (n=14 [7%]), and the capsular release group 
(n=8 [4%]; table 2).
At the primary endpoint of 12 months, many partic i-
pants had improved to nearly full shoulder functioning, 
with a median overall OSS of 43 (out of 48) points, 
compared with an initial median overall OSS of 20 points. 
Excluding the participants for whom no OSS data were 
available at any follow-up point, we analysed the primary 
outcome in 189 (94%) of 201 participants who were 
randomly assigned to receive manipulation, 191 (94%) of 
203 participants randomly assigned to receive capsular 
release, and 93 (94%) of 99 participants randomly assigned 
to receive early structured physiotherapy. Par ticipants 
randomly assigned to arthroscopic capsular release had 
statistically significantly higher (ie, better) OSS scores 
than those assigned to manipulation under anaesthesia 
(40·3 vs 38·3 points; difference 2·01 points, 95% CI 
0·10 to 3·91) or to early structured physiotherapy 
(40·3 vs 37·2 points; difference 3·06 points, 0·71 to 5·41). 
The manipula tion group had higher mean OSS scores 
than the physiotherapy group (38·3 vs 37·2 points; 
difference 1·05 points, –1·28 to 3·39; figure 2). Mean 
estimates were less than the minimal clinically important 
effect size of 4–5 OSS points (table 3). For the short-term 
follow-up at 3 months after randomisation, capsular 
release had lower (ie, worse) outcomes than the other two 
interventions. Differences of clinically important mag-
nitude were included in the 95% CIs for the benefit of 
Mean estimates MUA vs ESP ACR vs ESP ACR vs MUA
MUA ACR ESP Mean difference 
(95% CI)
p value Mean difference 
(95% CI)
p value Mean difference 
(95% CI)
p value
OSS*
3 months 30·2 26·9 31·6 –1·36 (–3·70 to 0·98) 0·25 –4·72 (–7·06 to –2·39) <0·0001 –3·36 (–5·27 to –1·45) 0·0006
6 months 37·1 35·9 34·9 2·15 (–0·12 to 4·42) 0·064 0·98 (–1·31 to 3·26) 0·40 –1·17 (–3·02 to 0·67) 0·21
12 months 38·3 40·3 37·2 1·05 (–1·28 to 3·39) 0·38 3·06 (0·71 to 5·41) 0·011 2·01 (0·10 to 3·91) 0·039
Average effect 
over 12 months 
35·2 34·4 34·6 0·61 (–1·31 to 2·53) 0·53 –0·23 (–2·15 to 1·70) 0·82 –0·84 (–2·41 to 0·72) 0·29
OSS time-adjusted†
3 months 28·2 26·0 29·4 –1·18 (–3·10 to 0·73) 0·23 –3·33 (–5·25 to –1·40) 0·0007 –2·14 (–3·71 to –0·57) 0·0076
6 months 32·5 31·5 32·7 –0·15 (–1·90 to 1·60) 0·87 –1·13 (–2·88 to 0·62) 0·21 –0·98 (–2·40 to 0·44) 0·18
12 months 41·1 42·5 39·2 1·92 (–0·16 to 4·00) 0·071 3·26 (1·18 to 5·35) 0·0022 1·35 (–0·33 to 3·02) 0·12
EQ-5D-5L‡
Baseline 0·46 0·43 0·40 0·05 (–0·01 to 0·12) 0·10 0·03 (–0·04 to 0·09) 0·42 –0·03 (–0·08 to 0·02) 0·28
3 months 0·63 0·57 0·61 0·03 (–0·03 to 0·08) 0·38 –0·04 (–0·10 to 0·02) 0·18 –0·06 (–0·11 to –0·02) 0·0056
6 months 0·73 0·68 0·68 0·05 (–0·01 to 0·10) 0·10 –0·004 (–0·06 to 0·05) 0·88 –0·05 (–0·10 to –0·01) 0·019
12 months 0·73 0·74 0·69 0·04 (–0·02 to 0·10) 0·20 0·05 (–0·02 to 0·10) 0·15 0·005 (–0·04 to 0·05) 0·85
QuickDASH§
3 months 38·8 44·4 37·1 1·77 (–3·41 to 6·96) 0·50 7·33 (2·16 to 12·49) 0·0054 5·55 (1·32 to 9·78) 0·010
6 months 27·7 27·4 29·2 –3·55 (–8·68 to 1·58) 0·18 –1·82 (–6·94 to 3·31) 0·49 1·73 (–2·39 to 5·86) 0·41
12 months 29·9 18·2 23·4 –0·50 (–5·70 to 4·70) 0·85 –5·20 (–10·42 to 0·02) 0·051 –4·71 (–8·91 to –0·50) 0·028
Pain NRS§
3 months 4·1 4·7 3·7 0·43 (–0·17 to 1·03) 0·16 1·02 (0·42 to 1·61) 0·0008 0·59 (0·10 to 1·07) 0·018
6 months 2·8 2·8 3·0 –0·19 (–0·78 to 0·40) 0·53 –0·14 (–0·74 to 0·45) 0·63 0·05 (–0·43 to 0·52) 0·85
12 months 2·4 1·7 2·5 –0·08 (–0·66 to 0·50) 0·78 –0·81 (–1·39 to –0·23) 0·0066 –0·73 (–1·20 to –0·25) 0·0026
Extent of recovery¶
3 months 51·4 54·0 53·9 –2·55 (–11·68 to 6·58) 0·58 0·11 (–9·02 to 9·23) 0·98 2·66 (–4·84 to 10·15) 0·49
6 months 31·9 34·7 38·6 –6·71 (–15·83 to 2·42) 0·15 –3·93 (–13·06 to 5·21) 0·40 2·78 (–4·50 to 10·06) 0·45
12 months 27·3 21·2 26·9 0·46 (–7·79 to 8·70) 0·91 –5·65 (–13·91 to 2·61) 0·18 –6·11 (–12·86 to 0·64) 0·076
MUA=manipulation under anaesthesia. ESP=early structured physiotherapy. ACR=arthroscopic capsular release. OSS=Oxford Shoulder Score. EQ-5D-5L=EuroQOL 5-Dimension questionnaire, 5-level version. 
QuickDASH=Quick Disabilities of the Arm, Shoulder, and Hand score. NRS=Numeric Rating Scale. *Linear mixed covariance pattern model adjusted for age, gender, diabetes, OSS at baseline (fixed effects), 
and site (random effect). †Linear mixed random intercept model adjusted for age, gender, diabetes, OSS at baseline (fixed effects), and site (random effect). ‡Univariate generalised linear model, including group 
as a fixed effect factor and baseline EQ-5D-5L score as a covariate. §Linear mixed covariance pattern model adjusted for age, gender, diabetes, QuickDASH at baseline (fixed effects), and site (random effect). 
¶Based on 0–100 Visual Analogue Scale of perceived need for further treatment. Linear mixed covariance pattern model adjusted for age, gender, diabetes, extent of recovery at baseline (fixed effects), and site 
(random effect). 
Table 3: Estimated mean outcome differences
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manipulation and physiotherapy compared with capsular 
release at 3 months, and for the benefit of capsular release 
com pared with physiotherapy at 12 months (table 3).
Compared with the primary analysis, group differences 
in the model adjusted for waiting times tended to be of 
smaller magnitude, with the exception of the difference 
between capsular release and physiotherapy at 12 months 
(3·26 points [95% CI 1·18 to 5·35] in favour of capsular 
release; appendix p 3). From the CACE analysis, the 
outcomes for participants who adhered to physiotherapy 
treatment remained lower than for participants in the 
surgery groups (–1·84 OSS points, –4·41 to 0·74), 
although the difference was not statistically significant 
(data not shown). Predictors of missingness were age 
and OSS outcome before being missing. These variables 
are already incorporated in the primary analysis. Sensi-
tivity analyses regarding the timing of questionnaire 
return and adjustment for employment status did not 
show marked differences from the primary results. 
There were no significant subgroup interactions.
Of the secondary outcomes, QuickDASH and shoulder 
pain followed a similar pattern to that of OSS, with 
significantly poorer outcomes for the capsular release 
group at 3 months but better outcomes at 12 months 
after randomisation compared with manipulation or 
physiotherapy (table 3). There were no clear group differ-
ences in the extent of recovery based on the treatment-
seeking VAS.
In total, ten serious adverse events were reported for 
nine (2%) of 503 participants, including eight (4%) of 
203 in the capsular release group and two (1%) of 201 in 
the manipulation group (table 4). One (<0·5%) participant 
in the capsular release group had a serious adverse event 
from non-trial physiotherapy (table 4). The numbers were 
insufficient for formal analysis. 33 non-serious adverse 
events were reported for 31 (6%) of 503 participants, with 
similar rates in the three groups (table 4). There was no 
evidence for statistical differences in the proportion of 
non-serious adverse events (p=0·19).
The base-case economic analysis with multiple impu-
tation showed that manipulation was £276·51 (95% CI 
65·67 to £487·35) more expensive per participant than 
was early structured physiotherapy. Capsular release was 
substantially more costly than physiotherapy (on average 
£1733·78 [1529·48 to 1938·06] more per participant) and 
manipulation (on average £1457·26 [1282·73 to 1631·79] 
more per participant). Overall, capsular release had worse 
QALYs than did manipulation under anaesthesia (mean 
difference –0·0293, –0·0616 to 0·0030) and manipulation 
had better QALYs than did physiotherapy (mean difference 
0·0396, –0·0008 to 0·0800). Manipulation was the inter-
vention most likely to be cost-effective at a threshold of 
£20 000 per QALY (manipulation 86%; physiotherapy 
14%; capsular release 0%; appendix pp 1–2).
Discussion
To our knowledge, UK FROST is the largest randomised 
clinical trial to date that has evaluated common surgical 
interventions and a specifically designed physiotherapy 
pathway with a steroid injection for the treatment of adults 
with a frozen shoulder in the UK NHS. Patient-reported 
shoulder pain and function improved substantially from 
Manipulation 
under anaesthesia 
(n=201)
Arthroscopic 
capsular release 
(n=203)
Early 
structured 
physiotherapy 
(n=99)
Serious adverse events
Attended accident and emergency for visual 
disturbance, headache, heaviness, and 
numbness of arm
1 (<0·5%)* 0 0
Chest infection 0 1 (<0·5%) 0
Decreased oxygen saturation 0 1 (<0·5%) 0
Deep vein thrombosis 0 1 (<0·5%)† 0
Elevated blood sugars (prolonging 
hospitalisation)
0 1 (<0·5%) 0
Hypoglycaemic seizure while under anaesthetic 0 1 (<0·5%) 0
Probable anterior dislocation 0 1 (<0·5%)‡ 0
Patient noticed facial drooping or weakness 
after surgery
0 1 (<0·5%) 0
Septic joint arthritis 1 (<0·5%) 0 0
Stroke (3 months after treatment) 0 1 (<0·5%) 0
Total 2 (1%) 8 (4%) 0
Non-serious adverse events
Additional diagnosis requiring further treatment 1 (<0·5%) 0 0
Adverse reaction to concurrent medication 0 1 (<0·5%) 0
Allergic reaction to dressing 0 1 (<0·5%) 0
Chest infection 1 (<0·5%) 0 0
Episode of inflammation 1 (<0·5%) 0 0
Infection 0 1 (<0·5%) 0
Injury to adjacent structures such as nerve, 
tendon, bone, or joint
1 (<0·5%) 1 (<0·5%)‡ 0
Ipsilateral face swelling, face flushed, and neck 
and face hot
1 (<0·5%) 0 0
Long head biceps tendon pain and rupture 0 0 1 (1%)
Neuropathic symptoms 1 (<0·5%) 2 (1%)§ 0
Patient investigated for neck problems 0 1 (<0·5%) 0
Persistent pain 0 1 (<0·5%) 1
Persistent pain requiring further treatment 1 (<0·5%) 1 (<0·5%) 0
Persistent stiffness and pain requiring treatment 1 (<0·5%) 0 0
Pins and needles to hand 1 (<0·5%) 0 0
Postprocedural worsening of shoulder pain 3 (1%) 3 (1%) 1 (1%)¶
Recurrent stiffness requiring further treatment 0 0 1 (1%)¶
Supraspinatus tendinopathy 0 0 1 (1%)
Surgical site infection 0 1 (<0·5%)|| 0
Transient hyperglycaemia, steroid flare, or joint 
sepsis following corticosteroid injection
3 (1%)** 0 0
Total 15 (7%) 13 (6%) 5 (5%)
Footnotes indicate when the treatment received was different from that of randomisation. *Recorded as receiving 
“no trial treatment”. †Recorded as receiving “non-trial physiotherapy”. ‡Received manipulation under anaesthesia. 
§One patient recorded as receiving “other” treatment (subacromial decompression). ¶Received arthroscopic capsular 
release. ||One patient recorded as receiving “other” treatment (capsular release without manipulation). **Received 
early structured physiotherapy.
Table 4: Adverse events by treatment arm as randomised
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baseline with all three trial treatments. At the primary 
endpoint of 12 months, the magnitude of difference of 
capsular release over manip ulation and physiotherapy 
was statistically significant but unlikely to be clinically 
important. This finding was consistent for all patient-
reported clinical outcomes. Arthroscopic capsular release 
was associated with higher risks, and manipulation under 
anaesthesia was the most cost-effective option. A detailed 
economic evaluation of relative cost-effectiveness of the 
three treatment options will be published separately, but 
the key results have been included because they are 
integral to interpreting the main clinical effectiveness 
findings.
The differences in patient-reported outcomes between 
the treatment groups at 3 months were influenced by 
longer waiting times for the surgical interventions 
(26 [13%] manipulation participants and 46 [23%] capsular 
participants commenced treatment after the 3-month 
follow-up). The planned analysis of our primary outcome, 
OSS, adjusted for variable waiting times between the 
three interventions using additional data that was collected 
on the day of treatment and 6 months after treatment. In 
this analysis, the difference in benefit of capsular release 
over physiotherapy at 12 months included a confidence 
interval that marginally overlapped with the minimal 
clinically important difference of 5 points. Therefore, clin-
ically meaningful group differences might potentially 
exist between capsular release and early structured 
physiotherapy in the wider population. We observed no 
meaningful differences in OSS between the two surgical 
interventions at any timepoint. Although patients with 
diabetes had poorer outcomes than patients without 
diabetes at all timepoints, we found no evidence of an 
effect on the primary outcome of participants’ diabetes 
status, receipt of previous physiotherapy, baseline treat-
ment preferences, or length of frozen shoulder symptoms 
at baseline.
Serious complications were rare, although the arthro-
scopic capsular release group was relatively less safe. 
Only two participants allocated to manipulation under 
anaesthesia had a serious complication. One of the 
participants in the capsular release group who was 
diagnosed with deep vein thrombosis received non-trial 
physiotherapy. There was, therefore, only a marginal 
difference in the safety profile between manipulation 
and physiotherapy. Although no participants allocated 
to physiotherapy had a serious complication, these 
participants were more likely to need further treatment. 
Participants in the capsular release group received fewest 
further treatments.
It is notable that the difference in OSS scores and the 
difference in health-related quality of life are similar, 
with only a small difference in OSS and QALYs across 
the groups. A possible trend of the capsular release group 
improving over time, which might continue with longer-
term follow-up, could be explained by the timing of the 
delivery of the interventions. This timing has been 
examined and does not alter the interpretation of the 
findings of the primary analysis. We are confident that 
important costs, including the costs of complications, 
were captured during the trial follow-up.
The strengths of this study were the pragmatic design, 
recruiting from 35 hospitals across a range of rural and 
urban areas, involving 90 surgeons and 285 physio-
therapists with minimal exclusions. This design makes 
the results generalisable and applicable to clinical 
practice in the UK. There were low levels of attrition 
within and between groups in the completion of the 
extensively validated patient-reported primary outcome, 
which measures pain and the effect of any stiffness on 
shoulder function.22 The rate of crossovers was also low. 
The statistical model meant that only 30 (6%) of 503 trial 
participants were not included in the primary analyses 
and consequently ensured that we achieved the planned 
statistical power of 90%. The results were robust to the 
sensitivity and subgroup analyses. Diagnosis of frozen 
shoulder can be challenging, and there is no reference 
standard for comparison.6 Because the visual estimation 
of external rotation has fair to good reliability,13 
restrictions (typically with pain) in both passive and 
active external rotation have been used as diagnostic 
criteria in clinical studies.7 This approach helped to 
ensure correct diagnoses in our study population. We 
also focused on delivering good standards of care, with 
surgeons using techniques with which they were familiar 
and most operations being conducted by consultant 
surgeons. Physiotherapy was delivered by qualified 
physiotherapists. Crucially, we standardised the physio-
therapy pathway in all groups of the trial to reduce 
variations in care between participants and trial groups. 
All participants were provided with written advice 
detailing the home exercises that they needed to do.20
The main limitation of the study was that participants 
who had capsular release or manipulation had to wait 
longer to receive their treatment. However, our additional 
analysis incorporating different waiting times confirmed 
that this factor did not influence the main trial results. For 
participants who started treatment, it was reassuring that 
their OSS was stable between baseline and start of 
treatment, but it is possible that only participants with a 
more resistant frozen shoulder had surgery. This analysis 
is also limited, because it reflects treatment effects at 
pragmatic follow-up times, accounting for the different 
outcome trajectories, rather than observing what would 
have happened if all three trial treatments were delivered 
at similar times. Given the nature of the trial treatments, 
masking participants and clinicians to treatment allocation 
was not possible or desirable in this pragmatic trial. 
However, the absence of any subgroup effect of participant 
baseline treatment preferences on OSS might in part 
mitigate concerns about the lack of masking. A further 
potential threat to study validity was non-compliance with 
the treatments. However, the trial findings were consistent 
when analysed both as randomised (intention-to-treat) 
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and with CACE analysis. Finally, only 6% of UK prac-
titioners were using hydrodilatation when we sur veyed 
practice to inform the design of UK FROST and 
consequently, this was not identified as a priority inter-
vention for evaluation.10 Its popularity has increased since 
then, and although recent small trials have compared 
hydrodilatation with manipulation, capsular release, and 
intra-articular steroid injections,33,34 evidence of its effec-
tiveness is inconclusive.
In conclusion, all three treatments in our study led to 
substantial improvements in patient-reported shoulder 
pain and function. None of the treatments were clearly 
superior. Arthroscopic capsular release resulted in the 
least number of further treatments but carried higher 
risks and costs. The early structured physiotherapy 
pathway with steroid injection could be accessed quickly 
in the NHS, but more patients who had physiotherapy 
needed further treatment. Manipulation under anaes-
thesia was the most cost-effective option but with a 
longer waiting time to access than physiotherapy. These 
findings should help clinicians to discuss treat ment 
options with patients during shared decision making 
and encourage surgeons to use capsular release more 
selectively when less costly and less invasive interventions 
fail.
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